Progression and treatment of incident lower urinary tract symptoms ( LUTS ) among men in the C alifornia M en's H ealth S tudy

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/110063/1/bju12810.pd

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Papanicolaou Screening Behavior in Mothers and Human Papillomavirus Vaccine Uptake in Adolescent Girls

Objectives. We investigated whether maternal attitude toward prevention, as indicated by history of seeking Papanicolaou (Pap) tests and contracting sexually transmitted infections, influenced human papillomavirus (HPV) vaccine uptake among their adolescent daughters

Quality of Preventive Care Before and After Prostate Cancer Diagnosis

Objective: To examine whether general preventive services were diminished in a cohort of men after their diagnosis of prostate cancer. Method: A total of 16,604 men enrolled in Kaiser Permanente Southern California who were newly diagnosed with prostate cancer from January 1, 2002, through December 31, 2009, were passively followed through EMRs to determine the use of preventive services, including screening for colorectal cancer (colonoscopy and/or fecal occult blood tests [FOBT]), tests for diabetes (glucose and hemoglobin A1c), heart disease (serum cholesterol, high-density lipoprotein [HDL], and triglycerides), and vaccinations (influenza and pneumococcal). Preventive service use was compared in the 2 years prior to and following prostate cancer diagnosis, using matched odds ratios (MORs) and 95% confidence intervals (CIs) in 2013. Results: Men were more likely to receive a flu vaccine (MOR 2.70, 95% CI 2.52–2.90), lipid tests (MOR 1.51, 95% CI 1.42–1.61), diabetes tests (MOR 2.13, 95% CI 2.00–2.26), and screening for colorectal cancer (MOR 1.80, 95% CI 1.71–1.89) in the 2 years after prostate cancer diagnosis, compared to before diagnosis. Men with advanced disease at diagnosis were more likely to receive all types of preventive services after diagnosis, compared to men with localized disease. Conclusion: Once diagnosed with prostate cancer in this setting, no less attention was paid to general preventive care, although there remains room for improvement in pneumococcal vaccination and colon cancer screening rates. The delivery of high-quality continuing care after diagnosis is critical for aging cancer patients

Quality of preventive care before and after prostate cancer diagnosis.

ObjectiveTo examine if the use of general preventive services were diminished in a cohort of men following their diagnosis of prostate cancer.Patients and methods16,604 men enrolled in Kaiser Permanente Southern California who were newly diagnosed with prostate cancer from January 1, 2002 through December 31, 2009 were passively followed through electronic medical records to determine the use of preventive services, including screening for colorectal cancer (colonoscopy and/or fecal occult blood tests (FOBT)), tests for diabetes (glucose and hemoglobin A1c) and heart disease (serum cholesterol, high density lipoprotein (HDL) and triglycerides) and vaccinations (influenza and pneumococcal). Preventive service use was compared in the two years prior to and following prostate cancer diagnosis using matched odds ratios (MOR) and 95% confidence intervals (CI) in 2013.ResultsMen were more likely to receive a flu vaccine (MOR: 2.70, 95% CI: 2.52-2.90), lipid tests (MOR: 1.51, 95% CI: 1.42-1.61), diabetes tests (MOR: 2.13, 95% CI: 2.00-2.26) and screening for colorectal cancer (MOR: 1.80, 95% CI: 1.71-1.89) in the two years after prostate cancer diagnosis compared to before. Men with advanced disease at diagnosis were more likely to receive all types of preventive services after diagnosis when compared to men with localized disease.ConclusionsOnce diagnosed with prostate cancer in this setting, no less attention was paid to general preventive care, although there remains room for improvement in pneumococcal vaccination and colon cancer screening rates. The delivery of high-quality continuing care after diagnosis is critical for aging cancer patients

Quality of preventive care before and after prostate cancer diagnosis.

ObjectiveTo examine if the use of general preventive services were diminished in a cohort of men following their diagnosis of prostate cancer.Patients and methods16,604 men enrolled in Kaiser Permanente Southern California who were newly diagnosed with prostate cancer from January 1, 2002 through December 31, 2009 were passively followed through electronic medical records to determine the use of preventive services, including screening for colorectal cancer (colonoscopy and/or fecal occult blood tests (FOBT)), tests for diabetes (glucose and hemoglobin A1c) and heart disease (serum cholesterol, high density lipoprotein (HDL) and triglycerides) and vaccinations (influenza and pneumococcal). Preventive service use was compared in the two years prior to and following prostate cancer diagnosis using matched odds ratios (MOR) and 95% confidence intervals (CI) in 2013.ResultsMen were more likely to receive a flu vaccine (MOR: 2.70, 95% CI: 2.52-2.90), lipid tests (MOR: 1.51, 95% CI: 1.42-1.61), diabetes tests (MOR: 2.13, 95% CI: 2.00-2.26) and screening for colorectal cancer (MOR: 1.80, 95% CI: 1.71-1.89) in the two years after prostate cancer diagnosis compared to before. Men with advanced disease at diagnosis were more likely to receive all types of preventive services after diagnosis when compared to men with localized disease.ConclusionsOnce diagnosed with prostate cancer in this setting, no less attention was paid to general preventive care, although there remains room for improvement in pneumococcal vaccination and colon cancer screening rates. The delivery of high-quality continuing care after diagnosis is critical for aging cancer patients

Exposure to statins post localized prostate cancer diagnosis and risk of metastasis among men who did not receive curative prostate cancer treatment

Abstract Background Few studies have evaluated the effect of statin exposure on metastasis risk among prostate cancer patients not receiving curative treatment. Methods We included men diagnosed with localized prostate cancer at an integrated health care system between 1997 and 2006 who did not receive curative treatment within 6 months of diagnosis. We followed these men until a metastatic event, disenrollment, death, or 12/31/2016. We collected all data from electronic health records supplemented by chart review. We used Cox regressions to examine the association between post‐diagnostic statin exposure and metastasis, controlling for clinical characteristics and pre‐diagnostic statin exposure. Results There were 4245 men included. Mean age of diagnosis was 68.02 years. 46.6% of men used statins after prostate cancer diagnosis. During follow‐up, 192 men developed metastasis (cumulative incidence rate: 14.5%). In the adjusted Cox model, statin use post‐prostate cancer diagnosis was not significantly associated with a metastatic event (HR = 0.97, 95% CI = 0.69, 1.36). Pre‐diagnostic statin use was also not associated with development of metastasis (HR = 0.76, 95% CI = 0.53, 1.10). We did not observe a dose‐response for the proportion of person‐time at‐risk post‐prostate cancer diagnosis on statins (HR = 0.98 per 10% increase in person‐time exposed [95% CI = 0.93, 1.03]). Conclusions We did not find an inverse association between post‐diagnosis statin exposure and metastasis development in localized prostate cancer patients who did not receive active treatment. Our results did not offer support to the chemopreventive potential of post‐diagnostic statin use among men on active surveillance